Scripps VIVO scripps research logo

  • Index
  • Log in
  • Home
  • People
  • Organizations
  • Research
  • Events
Search form

Synergistic neutralization of a chimeric SIV/HIV type 1 virus with combinations of human anti-HIV type 1 envelope monoclonal antibodies or hyperimmune globulins

Academic Article
uri icon
  • Overview
  • Identity
  • Additional Document Info
  • View All
scroll to property group menus

Overview

authors

  • Baba, T. W.
  • Sodroski, J.
  • ZollaPazner, S.
  • Gorny, M. K.
  • Robinson, J.
  • Posner, M. R.
  • Katinger, H.
  • Barbas III, Carlos
  • Burton, Dennis
  • Chou, T. C.
  • Ruprecht, R. M.
  • Li, A.

publication date

  • 1997

journal

  • AIDS Research and Human Retroviruses  Journal

abstract

  • A panel of 14 human IgG monoclonal antibodies (MAbs) specific for envelope antigens of the human immunodeficiency virus type 1 (HIV-1), 2 high-titer human anti-HIV-1 immunoglobulin (HIVIG) preparations, and 15 combinations of MAbs or MAb/HIVIG were tested for their ability to neutralize infection of cultured human T cells (MT-2) with a chimeric simian immunodeficiency virus (SHIV-vpu+), which expressed HIV-1 IIIB envelope antigens. Eleven MAbs and both HIVIGs were neutralizing. When used alone, the anti-CD4-binding site MAb b12, the anti-gp41 MAb 2F5, and the anti-gp120 MAb 2G12 were the most potent. When combination regimens involving two MAbs targeting different epitopes were tested, synergy was seen in all paired MAbs, except for one combination that revealed additive effects. The lowest effective antibody concentration for 50% viral neutralization (EC50) and EC90 were achieved with combinations of MAbs b12, 2F5, 2G12, and the anti-V3 MAb 694/98D. Depending on the combination regimen, the concentration of MAbs required to reach 90% virus neutralization was reduced approximately 2- to 25-fold as compared to the dose requirement of individual MAbs to produce the same effect. Synergy of the combination regimens implies that combinations of antibodies may have a role in passive immunoprophylaxis against HIV-1. The ability of SHIV to replicate in rhesus macaques will allow us to test such approaches in vivo.

subject areas

  • Animals
  • Antibodies, Monoclonal
  • Antigens, Viral
  • Cells, Cultured
  • Chimera
  • Drug Synergism
  • HIV Antibodies
  • HIV-1
  • Human Immunodeficiency Virus Proteins
  • Humans
  • Immunoglobulins
  • Macaca mulatta
  • Neutralization Tests
  • Simian Immunodeficiency Virus
  • Viral Envelope Proteins
  • Viral Regulatory and Accessory Proteins
scroll to property group menus

Identity

International Standard Serial Number (ISSN)

  • 0889-2229

Digital Object Identifier (DOI)

  • 10.1089/aid.1997.13.647

PubMed ID

  • 9168233
scroll to property group menus

Additional Document Info

start page

  • 647

end page

  • 656

volume

  • 13

issue

  • 8

©2021 The Scripps Research Institute | Terms of Use | Powered by VIVO

  • About
  • Contact Us
  • Support